- Conditions
- Peripheral Arterial Disease, Paclitaxel Adverse Reaction, Safety Issues
- Interventions
- Retrospective data collection
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 66 Years and older
- Enrollment
- 168,553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 33,598
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
- Conditions
- Heart Failure
- Interventions
- AMG 986
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Eastern Equine Encephalitis
- Interventions
- Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Fort Deterick, Maryland
- Conditions
- Pulmonary Arterial Hypertension PAH
- Interventions
- Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
- Other · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cerebrovascular Accident
- Interventions
- Abciximab (ReoPro) and Reteplase (Retavase)
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Takoma Park, Maryland
- Conditions
- Chronic Immune Thrombocytopenia
- Interventions
- Panzyga
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Sacramento, California • Minneapolis, Minnesota • Rochester, Minnesota + 5 more
- Conditions
- Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
- Interventions
- ARQ 621
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Intravitreal autologous CD34+ cells
- Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Neuropathic Pain From Lumbosacral Radiculopathy
- Interventions
- KLS-2031, Placebo
- Drug · Other
- Lead sponsor
- Kolon Life Science
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- RX-3117
- Drug
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Weeki Wachee, Florida • Joliet, Illinois + 7 more
- Conditions
- Chronic Kidney Disease, Acute Kidney Injury
- Interventions
- 75 mg / 6 mL VFI™
- Device
- Lead sponsor
- FAST BioMedical
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Glabellar Lines, Lateral Canthal Lines
- Interventions
- MT10109L, Placebo
- Drug
- Lead sponsor
- Medy-Tox
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 9
- States / cities
- Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more
- Conditions
- Type 2 Diabetes
- Interventions
- Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Luspatercept, Epoetin Alfa
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 33
- States / cities
- Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
- Conditions
- Postoperative Ileus
- Interventions
- 5% dextrose in water, TZP-101
- Drug
- Lead sponsor
- Tranzyme, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more
- Conditions
- Diagnosis of Adult Growth Hormone Deficiency (AGDH)
- Interventions
- AEZS-130 (formerly ARD-07), L-ARG+GHRH
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 13
- States / cities
- Tempe, Arizona • Los Angeles, California • Torrance, California + 9 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more
- Conditions
- Psoriasis
- Interventions
- AN2728 ointment, 2%, Ointment Vehicle
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
- Conditions
- Migraine Prophylaxis
- Interventions
- Atogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
- Conditions
- Hematologic Neoplasms
- Interventions
- Hemanext ONE system, Conventional RBCs
- Device
- Lead sponsor
- Hemanext
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dry Eye
- Interventions
- EBI-005-1, EBI-005-1 Placebo
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Migraine
- Interventions
- Ubrogepant, Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Atlanta, Georgia • Austin, Texas + 1 more
- Conditions
- Colitis, Crohn's Disease, Inflammatory Bowel Disease
- Interventions
- Immunologic Monitoring
- Other
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland